LEISH-F3/SLA-SE adjuvant vaccine (IDRI)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameLEISH-F3/SLA-SE adjuvant vaccine (IDRI)

Drug Alias NameSLA-SE-adjuvanted leishmaniasis vaccine (Infectious Disease Research Institute)

ClassificationBiologics > Protein drugs > Recombinant proteinVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsLeishmania donovani infection

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAlbania

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAccess to Advanced Health Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAccess to Advanced Health Institute

Active IndicationsN/A

Inactive IndicationsLeishmania donovani infection

Other Information

ATC CodeN/A